Working… Menu

Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma (STALLONe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01460901
Recruitment Status : Completed
First Posted : October 27, 2011
Results First Posted : July 23, 2019
Last Update Posted : July 23, 2019
Center for Cell and Gene Therapy, Baylor College of Medicine
Information provided by (Responsible Party):
Doug Myers, Children's Mercy Hospital Kansas City

Brief Summary:
This is a single-center, investigator-initiated, single-arm, pilot study of post-allogeneic transplant, adoptive immunotherapy for the treatment of patients with relapsed/refractory neuroblastoma expressing the mesenchymal tumor marker GD2. Three patients will be treated. The study will focus on the safety and efficacy of allogeneic, donor derived viral specific cytotoxic T-lymphocytes, retrovirally transduced to express a chimeric antigen receptor specific for disialoganglioside, GD2, expressed on neuroblastoma.

Condition or disease Intervention/treatment Phase
Neuroblastoma Biological: GD2 CAR modified Tri-virus specific cytotoxic t-cells Phase 1

Detailed Description:
Neuroblastoma (NB) is the most common extracranial tumor of childhood and prognosis for patients with relapsed or refractory disease is < 10% and there is no standard therapy for these patients. Research toward immunotherapeutic agents has intensified as monoclonal antibody targeting GD2, when incorporated into upfront NB therapy, prolongs survival. Allogeneic Hematopoietic stem cell transplantation (HSCT) has been utilized in patients with NB with evidence of a graft versus tumor (GVT) effect but transplant related mortality (TRM) has nullified the survival benefit. In an effort to harness the GVT effect of allogeneic transplant and lower TRM, harvested viral specific cytotoxic T-cells from the donor will be infused early post-HSCT to the HSCT recipient to shorten the recovery of immunity toward the most significant viral infections. The investigators will also retrovirally transduce the viral specific CTL with a chimeric antigen receptor (CAR) gene complex such that the tV-CTL can expand, via their native T-cell receptors in response to viral infections post-HSCT and carry the capability of killing tumor cells through their transduced receptor which, on the extracellular component of the CAR, has specificity for GD2 expressed on the surface of NB. In essence, the investigators intend to take the specificity of the monoclonal antibody to GD2, already utilized in therapy for NB, and combine this specificity with the cytotoxicity of T-cells to target NB. The investigators hypothesize that the infusion will be safe and viral specificity of the tV-CTL will provide long term immunity to both viral infections and the investigators will see anti-tumor effects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Donor Derived,Gene Modified, Multi-virus-specific, Cytotoxic T-Lymphocytes Redirected to GD2 for Relapsed/Refractory Neuroblastoma Post-allo Stem Cell Transplantation With Submyeloblative Conditioning
Study Start Date : October 2012
Actual Primary Completion Date : January 2015
Actual Study Completion Date : January 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Neuroblastoma

Arm Intervention/treatment
Experimental: GD2 CAR modified Tri-virus CTL infusion
A single infusion of 2x10e6 cells per meter squared was performed 30 to 120 days following allogeneic stem cell transplant.
Biological: GD2 CAR modified Tri-virus specific cytotoxic t-cells
This is a feasibility study to assess safety of an infusion of chimeric-antigen receptor gene modified allogeneic virus specific T lymphocytes after reduced intensity allogeneic stem cell transplant. Three patients were treated and safety was evaluated. Patients received a single infusion of 2x10e6/m2 donor derived, GD2 CAR modified, tri-virus specific CTL performed 30-120 days after allogeneic stem cell transplantation

Primary Outcome Measures :
  1. Number of Participants With Immediate and Short Term Toxicity of Infusion Over 8 Weeks [ Time Frame: Post infusion week 8 ]

    Immediate: Patients were monitored following infusion to assess for toxicity related to infusion. Potential toxicities related to cellular therapy infusions, such as allergic reaction to the cellular product or cryopreservation media, hemolytic reactions, volume overload, and hemodynamic instability, were monitored.

    Short Term: Patients were monitored for 8 weeks for short term toxicity related to infusion. Such adverse reactions monitored were acute graft versus host disease and cytokine release syndrome.

  2. Peak Transgene Copy Number Per 1000ng PBMC DNA [ Time Frame: 1 year ]
    Peak Transgene Copy Number per 1000ng PBMC DNA from peripheral blood samples measured during study participation.

  3. Death Within 8 Weeks of Infusion [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. Peak Viral Specific SFU/2x10e5 Mononuclear Cells Per Well [ Time Frame: up to 1 year ]

    The following analyses were performed on peripheral blood samples from patients at protocol assigned time points (pre-infusion, post-infusion at 4 hrs, weeks 1,2,4,6 and 8, month 3, 6 and 12:

    ELISPOT assay for CMV, Adenovirus and EBV specific CTL reported as SFU (spot forming unit) per 2x10e5 mononuclear cells

  2. Maximum Tumor Response (RECIST 1.1) [ Time Frame: 1 year ]
    Pre and post-therapy evaluation by modalities consistent with prior disease evaluation in each patient. When possible, tumors were assessed per Response Evaluation Criteria In Solid Tumors (RECIST v1.0): Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >/=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) at least a 20% increase in the sum of diameters of target lesions; Stable Disease (SD) neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Bone marrow aspirations and biopsies were evaluated by histopathology and appropriate immunohistochemistry; Modified Curie score was used for MIBG evaluation.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Months to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Allogeneic transduced tV-CTLs with >15% expression of 14g2a.zeta chimeric antigen receptor
  • Patient or responsible person must be able to understand and sign a permission/assent or consent form for infusion
  • Age 18 months through 17 years at time of relapse/progression
  • Life expectancy >8weeks
  • Karnofsky score 60% or greater if 10 yrs old or older. Lansky score 60% or greater if under 10 yrs old
  • Patient must be HIV negative
  • ANC >500
  • Pulse ox>90% on room air
  • AST/ALT/direct bili <5x upper limit of normal
  • Recovered from toxic effects of all prior chemotherapy
  • Absence of human/anti-mouse antibody (HAMA) (patients who have received prior therapy with murine antibodies)
  • >50% donor engraftment

Exclusion Criteria:

  • Patient pregnant or lactating or refuses birth control methods
  • HIV positive
  • Uncontrolled intercurrent infection
  • Renal failure (creatinine clearance <40ml/min/1.73m2)
  • Active hepatitis or cirrhosis with bilirubin, AST, ALT >5xnormal
  • Rapidly progressive disease
  • Currently receiving any investigational drugs
  • Tumor potentially causing airway obstruction
  • Cardiomegaly or bilateral pulmonary infiltrates on CXR
  • Receiving >0.25mg/kg/day methylprednisolone or equivalent systemic steroid. Topical steroid therapy is acceptable
  • Receiving more than one lymphocyte inhibiting agent (ex. Tacrolimus/CSA and MMF or other similar agent
  • Patients relapsing or progressing before the age of 18 months from Stage I/II disease, and/or those who, in the opinion of their oncologist, may benefit from further conventional therapy
  • Donor lymphocyte infusion in last 28 days
  • Evidence of GvHD greater than or equal to grade 2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01460901

Layout table for location information
United States, Missouri
Children's Mercy Hospital
Kansas City, Missouri, United States, 64108
Sponsors and Collaborators
Children's Mercy Hospital Kansas City
Center for Cell and Gene Therapy, Baylor College of Medicine
Layout table for investigator information
Principal Investigator: Doug Myers, MD Children's Mercy Hospital Kansas City
Additional Information:
Layout table for additonal information
Responsible Party: Doug Myers, Principal Investigator, Children's Mercy Hospital Kansas City Identifier: NCT01460901    
Other Study ID Numbers: STALLONe
00038 ( Other Identifier: Production Assistance for Cellular Therapy (PACT) )
First Posted: October 27, 2011    Key Record Dates
Results First Posted: July 23, 2019
Last Update Posted: July 23, 2019
Last Verified: July 2019
Keywords provided by Doug Myers, Children's Mercy Hospital Kansas City:
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue